Drug reps today are facing an increasingly strong imperative to depart from traditional promotional activities simply aimed at getting doctors’ prescriptions. For these reps to shift to communications focusing on proper drug use, the key will be their performance reviews.…
HOME > ACADEMIA
ACADEMIA
- Revised Hyperuricemia Treatment Guidelines Recommend Uric Acid Production Inhibitors to Prevent Kidney Function Decline
January 21, 2019
- Concomitant Insulin a Must for Suglat Use in Type 1 Diabetes: Specialist
January 18, 2019
- 8-Week Treatment with Maviret a Promising First-Line Option for Hepatitis C: Hepatologist
January 11, 2019
- Tokyo Medical and Dental Univ. to Launch Investigator-Led Trial for JAK Inhibitor for CAEBV
January 10, 2019
- Keio Univ. Board OKs World’s 1st iPS Cell Clinical Research for Spinal Cord Injuries
November 29, 2018
- Health Economist Calls for Robust Appraisal Process in Japan CEA System
November 20, 2018
- World’s 1st, Keio Univ. Plans iPS Cell Clinical Research for Spinal Cord Injuries
November 15, 2018
- Hematology Specialist Advises Caution in Using Hemlibra in Children
October 30, 2018
- Research Group Builds New Pathogenic Variants Database for Japanese Hereditary Breast Cancer
October 16, 2018
- I/O Pioneers Win Nobel Prize in Medicine; Honjo Prods Japan Firms to Make More Academic Investment at Home
October 2, 2018
- New Treatment GL for Statin Intolerance Compiled by Atherosclerosis Society, 3 Other Academic Societies
October 1, 2018
- Opdivo Holds Promise as New Option for Malignant Pleural Mesothelioma: Pulmonary Specialist
September 21, 2018
- Oncologist Hails Tagrisso Approval for 1st-Line Lung Cancer Treatment
September 14, 2018
- 3-Year Cancer Survival Rate in Japan at 71%: NCC
September 13, 2018
- Japan Cancer Association to Release Statement on Health Spending at Sept. Meeting
August 24, 2018
- Only 30% of Patients Took Thyroid Tests before Receiving Dementia Meds: Survey
July 25, 2018
- Debut of siRNA Therapeutic Looming on Horizon; Alnylam’s Patisiran Might Be Filed in Japan Too
July 24, 2018
- Japanese Society of Medical Oncology to Update I/O Guidelines in October
July 18, 2018
- Hematologist Optimistic about New Drugs for AML Including SMO and BCL-2 Inhibitors as Well as FLT3 Inhibitors
July 11, 2018
- Doctors Need Solid Understanding of Hereditary Cancer When Prescribing Lynparza for Breast Cancer: Prof.
July 5, 2018
ページ
Eisai is aiming to notch up a compound annual growth rate (CAGR) of 20% over FY2020-2025 under its five-year business plan. The primary driver will certainly be Lenvima (lenvatinib), a fast-growing cancer drug that has earned an up-to-US$5.76 billion alliance…
Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
Look into the heart of every successful company, the businesses that have made a real impact on the world, and you’ll notice they all share a common trait.The people. But not just any people, as Jim Collins famously said…“People are…